The Economic Times reports Bayer AG is weighing opportunities in products aimed at side effects people get on GLP-1 drugs.
Recap by typeshit. Post by @economictimes on Instagram.
A short piece on how cravings and snacking urges may change for people taking GLP-1 drugs. Details are thin, so tap through for the full story.
The writer cites a Gallup survey putting about 11 percent of Americans on GLP-1s and argues the real share is likely higher, and wants use discussed openly.
11:37
A 63 year old creator walks through six months on tirzepatide and a 48 pound drop, sharing a personal account of the experience.
Philstar Life looks at famous names linked to Ozempic for weight loss. Only a search title came through, so details are thin until you open the source.
Bloomberg Law reports Lilly has widened its legal push against sellers of knockoff versions of its experimental obesity drug, which is still unapproved.
Healio
Researchers compared 22,694 first-time semaglutide users with 229,640 controls. Lead author Mille Dybdal Bager says the link shouldn't be read as cause and effect.
Loading…